Tysabri Progressive Multifocal Leukoencephalopathy Settlement: Statute of Limitations for Tysabri in Georgia

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Targeted Risk Awareness

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical risks and therapeutic benefits. This legacy context has empowered individuals to navigate complex healthcare landscapes, from routine preventive measures to the nuanced evaluation of prescription treatments. Within this broad framework, the focus has naturally expanded to include the long-term implications of specific pharmaceutical interventions, particularly those associated with significant adverse outcomes. One such area of heightened concern involves the use of immunomodulatory therapies, where the balance between disease control and potential complications demands careful scrutiny. As public awareness has matured, attention has shifted from general health maintenance to the specific, real-world consequences of exposure to certain biologic agents. This pivot is especially relevant in occupational and clinical settings where prolonged or repeated administration of such therapies occurs. The transition from a general health perspective to a targeted exposure concern is exemplified by the case of Tysabri (natalizumab) and its established association with progressive multifocal leukoencephalopathy (PML). For individuals in Georgia who have been exposed to this medication, understanding the legal and temporal boundaries for seeking redress becomes paramount. Thus, the legacy of general health education now converges with a focused inquiry into the statute of limitations for Tysabri-related PML settlements in Georgia, marking a shift from broad informational stewardship to specific occupational and clinical risk management.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for moderate-to-severe active Crohn's disease in adults who have had an inadequate response to or cannot tolerate conventional therapies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, but Tysabri-treated patients are at elevated risk even without other immunosuppressive conditions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information instructs healthcare professionals to consider these factors in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled in this program, read the Medication Guide, understand the risks, and complete and sign the Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Pharmacies and infusion centers must be specially certified to dispense or infuse Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

The clinical presentation of PML is variable and can include progressive neurological deficits such as weakness, visual disturbances, cognitive decline, ataxia, and speech difficulties. Diagnosis is typically confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via PCR. The prescribing information mandates that healthcare professionals monitor patients on Tysabri for any new sign or symptom that may be suggestive of PML and that Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these precautions, PML can still develop, and the outcome is often severe disability or death.

Mechanism of Action and Risk Factors

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 beta-1 integrin on the surface of lymphocytes, blocking their adhesion to endothelial cells and thereby preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance in the brain. The JC virus, which is latent in many individuals, can reactivate and cause lytic infection of oligodendrocytes in the absence of adequate T-cell monitoring, leading to PML. The risk is compounded by the fact that Tysabri does not directly kill immune cells but rather alters their trafficking, meaning that the immunosuppressive effect is selective and may not be fully appreciated by patients or clinicians.

Adequacy of Warnings and Legal Implications in Georgia

Regarding the adequacy of warnings, the boxed warning on the Tysabri label explicitly states that the drug increases the risk of PML and that it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also identifies the three known risk factors and instructs clinicians to consider them when initiating and continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, the adequacy of these warnings in practice may be questioned if patients were not fully informed of the magnitude of risk or if the TOUCH program was not effectively implemented. For affected patients in Georgia, settlement considerations may depend on whether the warnings provided were sufficient to allow informed consent and whether the patient's specific risk factors were appropriately assessed and communicated. The timeline between Tysabri exposure and documented PML harm can vary. The label notes that PML has occurred in patients who have received Tysabri, with longer treatment duration (especially beyond two years) being a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In some cases, PML may develop after only a few months of therapy, but the risk increases with cumulative exposure. The latency period from initial JC virus reactivation to clinical symptoms can be weeks to months, and diagnosis may be delayed if symptoms are subtle or attributed to the underlying disease. For settlement purposes, the date of first Tysabri infusion, the date of PML diagnosis, and the date of first symptoms are critical for establishing the statute of limitations in Georgia. In Georgia, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this discovery date may be the date of diagnosis or the date when symptoms first became apparent and were linked to Tysabri. Given the severity of PML, affected patients or their families should promptly seek legal counsel to determine whether their claim falls within the applicable time frame. Settlement amounts in Tysabri-related PML cases have historically been substantial, reflecting the catastrophic nature of the injury, but individual outcomes depend on factors such as the strength of evidence linking the harm to inadequate warnings, the patient's risk factor profile, and the jurisdiction's laws.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Georgia?

In Georgia, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this discovery date may be the date of diagnosis or when symptoms first became apparent and were linked to Tysabri. It is crucial to seek legal counsel promptly to determine if your claim falls within this time frame.

What are the known risk factors for developing PML while on Tysabri?

Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.